Skip to main content

Table 1 Baseline characteristics at antiretroviral therapy initiation

From: Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting

 

eGFR (ml/min/1.73m2)

≥ 90

N = 2528 (80.5%)

60–89

N = 517 (16.5%)

<  60

N = 93 (3.0%)

P-value

Total

N = 3138

Age (years)

36.2 (30.7–43.2)

42.1 (36.2–48.1)

41.1 (35.8–47.6)

< 0.001

37.3 (31.4–44.5)

Female

1807 (71.5)

390 (75.4)

61 (65.6)

0.072

2258 (72.0)

Age (years)

< 30

546 (21.6)

45 (8.7)

4 (4.3)

< 0.001

595 (19.0)

[30–40]

1108 (43.8)

168 (32.5)

37 (39.8)

 

1313 (41.8)

[40–50]

598 (23.7)

199 (38.5)

34 (36.6)

 

831 (26.5)

≥ 50

276 (10.9)

105 (20.3)

18 (19.3)

 

399 (12.7)

BMI (Kg/m2)a

20.4 (18.3–23.1)

21.1 (18.6–24.1)

19.5 (17.4–22.2)

< 0.001

20.5 (18.3–23.3)

BMI (Kg/m2)a

< 18.5

694 (27.5)

123 (24.0)

38 (40.9)

< 0.001

855 (27.3)

[18.5–25]

1483 (58.8)

287 (55.9)

48 (51.6)

 

1818 (58.1)

[25–30]

268 (10.6)

70 (13.7)

6 (6.4)

 

344 (11.0)

≥ 30

77 (3.1)

33 (6.4)

1 (1.1)

 

111 (3.6)

HIV type

1

2371 (93.8)

476 (92.1)

91 (97.8)

0.326

2938 (93.6)

1 + 2

92 (3.6)

23 (4.4)

1 (1.1)

 

116 (3.7)

2

65 (2.6)

18 (3.5)

1 (1.1)

 

84 (2.7)

WHO stagea

1

638 (25.3)

99 (19.4)

8 (8.6)

< 0.001

745 (23.8)

2

587 (23.3)

111 (21.7)

20 (21.5)

 

718 (23.0)

3

1118 (44.3)

252 (49.3)

48 (51.6)

 

1418 (45.4)

4

178 (7.1)

49 (9.6)

17 (18.3)

 

244 (7.8)

CD4 count (cells/μl)a

188 (91–288)

169 (93–253)

120 (56–206)

< 0.001

183 (89–279)

CD4 count < 200 cells/μla

1331 (53.4)

295 (57.8)

64 (73.6)

< 0.001

1690 (54.7)

CD4 count < 100 cells/μla

674 (27.1)

139 (27.3)

40 (46.0)

0.001

853 (27.6)

Hemoglobin (g/dL)a

10.7 (9.5–12)

10.9 (9.3–12.0)

9.0 (7.6–10.5)

< 0.001

10.7 (9.5–12)

Cholesterol (mmol/ml)a

3.5 (2.8–4.1)

3.9 (3.1–4.8)

3.7 (3.0–4.4)

< 0.001

3.5 (2.8–4.2)

Triglyceride (mmol/ml)a

1 (0.7–1.3)

1.1 (0.8–1.7)

1.5 (1.1–2.1)

< 0.001

1.0 (0.8–1.4)

ALT (U/L)a

18 (12–28)

18 (12–30)

19 (13–33)

0.406

18 (12–29)

Glycemia (mmol/ml)a

4.8 (4.4–5.2)

5 (4.6–5.5)

4.9 (4.5–5.4)

< 0.001

4.8 (4.4–5.3)

Diabetesa

10 (0.4)

1 (0.2)

1 (1.1)

0.317

12 (0.4)

High blood pressurea

187 (7.5)

67 (13.2)

13 (14.0)

< 0.001

267 (8.6)

initial antiretroviral therapies

 AZT/3TC + NNRTI

1031 (40.8)

201 (38.9)

23 (24.7)

< 0.001

1255 (40.0)

 AZT/3TC + PI

157 (6.2)

41 (7.9)

4 (4.3)

202 (6.4)

 TDF/3TC or TDF/FTC + NNRTI

798 (31.5)

179 (36.6)

25 (26.9)

1002 (31.9)

 TDF/3TC or TDF/FTC + PI

68 (2.7)

15 (2.9)

0 (0)

83 (2.6)

 TDF/FTC + RAL

1 (0.0)

0 (0)

0 (0)

1 (0.0)

 d4T/3TC + NNRTI

399 (15.8)

68 (13.1)

17 (18.3)

484 (15.4)

 d4T/3TC + PI

68 (2.7)

6 (1.2)

0 (0)

74 (2.4)

 ABC/3TC + NNRTI

4 (0.2)

6 (1.2)

23 (24.7)

33 (1.1)

 ABC/3TC + AZT

1 (0.0)

1 (0.2)

0 (0)

2 (0.1)

 ABC/3TC or ABC/ddI + PI

1 (0.0)

0 (0)

1 (1.1)

2 (0.1)

  1. Data are median (IQR) or n (%); eGFR estimated Glomerular Filtration Rate, BMI body mass index, WHO World Health Organization, ALT alanine aminotransferase, AZT Zidovudine, 3TC Lamivudine, NNRTI non-nucleoside reverse transcriptase inhibitor, TDF Tenofovir Disoproxil Fumarate, FTC emtricitabine, d4T Stavudine, PI protease inhibitor, ABC abacavir, ddI didanosine
  2. aThere were 2 missing data for marital status, 10 missing data for BMI, 13 missing data for WHO stage, 49 missing data for CD4 count, 76 missing data for hemoglobin, 34 missing data for blood pressure, 29 missing data for glycemia, 64 missing data for ALT, 1131 missing data for cholesterol and 1133 missing data for triglyceride
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us